Actuate Therapeutics

We dissect potential moat components recognizing there is no approved product yet. Intangible assets: 45/100. Composition‑of‑matter coverage for elraglusib polymorphs (multiple US and ex‑US grants) that expire around 2038, plus Fast Track in PDAC and several US orphan designations, provide time‑limited protection if approved. Weight 40%.

Switching costs: 10/100. Oncologists can change regimens; without guideline inclusion and multi‑year outcomes data, stickiness is low. Weight 25%. Network effects: 0/100. No two‑sided network or data moat today. Weight 10%.

Cost advantage: 5/100. Semi‑virtual model with single‑source DS manufacturing in China and no long‑term supply contracts implies no structural cost edge. Weight 15%. Efficient scale: 10/100. If approved for rare pediatric indications, market scale may limit entrants, but PDAC is competitive and capital intensive. Weight 10%.

Weighted result ≈ 23/100. Overall, the moat is only a possibility pending regulatory success and commercialization.